Congratulations on the Launch of Lunan Pharma's Yilida® (Rituximab Injection)! Bioknow EDC Provided End-to-End Support for Clinical Data Management

At the listing conference, Liu Zhong, Vice General Manager of Lunan Pharmaceutical Group Corporation, solemnly announced this exciting news. More than 150 authoritative experts in the field of hematological oncology from over 40 participating research centers across China gathered together to witness this historic moment.

The birth of Yilida® is built on a solid scientific foundation. Professor Li Dengju from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, emphasized: "The Phase III study covered 63 centers and 417 patients with DLBCL. The main clinical focus IRC-ORR comparison data shows,Similar efficacy and safety compared to the original drug, with significant economic advantages.”

This means that Chinese patients now have a new treatment option that is effective, safe, and more accessible.

The successful launch of Yilida® is inseparable from the strong support of a digitalized clinical research system. The bioknow EDC system provided comprehensive support for its key clinical research, utilizing AI and big data technologies to ensure real-time, standardized, and accurate entry of massive amounts of data from multiple centers and participants. It addressed the challenges of efficient data collection and management in clinical trials, achieving intelligent data collection and report generation. While ensuring data quality, it shortened trial duration, fully supporting the smooth launch of Yilida®.

Bioknow extends sincere congratulations on the launch of Yilida® by Lunan Pharmaceutical, and looks forward to continuing collaboration in the future, writing a new chapter together!